InflaRx N.V. (FRA:IF0)

Market Cap	96.28M +66.0%
Revenue (ttm)	29.33K -82.3%
Net Income	-45.63M
EPS	-0.68
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5,756
Open	1.299
Previous Close	1.278
Day's Range	1.250 - 1.320
52-Week Range	0.623 - 1.976
Beta	n/a
RSI	65.15
Earnings Date	May 7, 2026

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its u...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 65
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IF0

Financial Performance

In 2025, InflaRx's revenue was 29,331, a decrease of -82.31% compared to the previous year's 165,789. Losses were -45.63 million, -0.93% less than in 2024.